Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dennis Woodling

Internal Medicine Montgomery, AL Medical Doctor

NPI 1972697464 CMS profile 43931

6940 Winton Blount Blvd, Montgomery, AL 36117

Open in the dashboard

General payments

$13,026

801 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dennis Woodling of Montgomery, AL is reported in the CMS Open Payments database as having received $13,026 across 801 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,877 100
2024 General $1,979 113
2023 General $1,945 116
2022 General $2,072 125
2021 General $1,914 126
2020 General $1,470 97
2019 General $1,770 124

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dennis Woodling
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Dennis Woodling were reported at $1,877. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Dennis Woodling Internal Medicine median Middle half National median
2019 $1,770 $159 $48–$570 $163
2020 $1,470 $119 $33–$402 $114
2021 $1,914 $135 $37–$521 $132
2022 $2,072 $141 $42–$496 $149
2023 $1,945 $149 $45–$519 $160
2024 $1,979 $154 $47–$537 $164
2025 $1,877 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,106 84 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,071 59 payments
  3. Pfizer Inc. $948 63 payments
  4. Novo Nordisk Inc $944 58 payments
  5. Lilly USA, LLC $868 61 payments
  6. AstraZeneca Pharmaceuticals LP $819 46 payments
  7. Astellas Pharma US Inc $680 35 payments
  8. GlaxoSmithKline, LLC. $626 40 payments
  9. Merck Sharp & Dohme Corporation $472 33 payments
  10. Abbott Laboratories $437 24 payments
  11. Other $5,056 298 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,941 800 payments
  2. Education $85 1 payment
Products named General payments · program years 2019–2025
  1. XIFAXAN $881 47 payments
  2. Ozempic $837 52 payments
  3. RYBELSUS $724 43 payments
  4. GEMTESA $620 33 payments
  5. TRELEGY ELLIPTA $537 35 payments
  6. ELIQUIS $530 32 payments
  7. UBRELVY $488 37 payments
  8. MOUNJARO $484 31 payments
  9. FARXIGA $451 26 payments
  10. BELSOMRA $369 26 payments
  11. Other $11,391 730 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 193 drugs

Part D claims

13,568

Median for Internal Medicine: 777

Drug cost

$1,325,651

Median for Internal Medicine: $73,373

Branded share of claims

26.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 151 $157,845
Myrbetriq Mirabegron Brand 175 $117,507
Jardiance Empagliflozin Brand 120 $104,217
Eliquis Apixaban Brand 96 $100,384
Ozempic Semaglutide Brand 71 $69,441
Farxiga Dapagliflozin Propanediol Brand 79 $63,623
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 60 $46,394
Vraylar Cariprazine Hcl Brand 25 $43,754
Janumet Sitagliptin Phos/Metformin Hcl Brand 53 $41,784
Linzess Linaclotide Brand 71 $38,040

The 10 drugs with the highest cost, of 193 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$92,981

Of which drugs: $2,744

Medicare patients

309

Average age 75

Services billed

2,288

180 women, 129 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Ischemic heart disease 27%
Diabetes 25%
Cancer 15%
Osteoporosis 14%
Atrial fibrillation 13%
Chronic kidney disease 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 14 30 $113
Injection, methylprednisolone acetate, 1 mg J1010 Office 14 726 $75

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $167
$167 27 —
MOUNJARO
  • Lilly USA, LLC $144
$144 151 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $141
$141 — —
TRULANCE
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $125
$125 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $112
$112 79 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

801 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record